Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

Proteomic Tests Poised For Clinical Market

Potential for earlier detection, higher sensitivity and specificity

CEO SUMMARY: Proteomics-based technology is developing rapidly. The strategic collaboration announced last month between Ciphergen Biosystems and Quest Diagnostics Incorporated is potentially worth $25 million. It is an expensive bet that next-generation proteomics tests soon to enter the clinical marketplace will provide high clinical utility and give physicians new diagnostic tools. NEW PROTEOMIC-BASED TECHNOLOGIES ARE …

Proteomic Tests Poised For Clinical Market Read More »

To access this post, you must purchase The Dark Report.



You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

Privacy Policy: We will never share your personal information.